Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8733712 | Critical Reviews in Oncology/Hematology | 2018 | 11 Pages |
Abstract
The results of current preclinical studies, the mechanism of action, and clinical efficacy of melatonin in breast cancer are reviewed in this paper. Melatonin alone or in combined administration seems to be appropriate drug for the treatment of early stages of breast cancer with documented low toxicity over a wide range of doses. These and other issues are also discussed.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Peter Kubatka, Pavol Zubor, Dietrich Busselberg, Taeg Kyu Kwon, Mariusz Adamek, Daniel Petrovic, Radka Opatrilova, Katarina Gazdikova, Martin Caprnda, Luis Rodrigo, Jan Danko, Peter Kruzliak,